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Inhibition of serum and 
glucocorticoid regulated kinase-1 
as novel therapy for cardiac 
arrhythmia disorders
Vassilios J. Bezzerides1,2, Aifeng Zhang1,4, Ling Xiao4, Bridget Simonson1,4, Santosh A. 
Khedkar1,6, Shiro Baba5, Filomena Ottaviano1, Stacey Lynch3, Katherine Hessler1, Alan C. 
Rigby1,3, David Milan4, Saumya Das1,4 & Anthony Rosenzweig1,4
Alterations in sodium flux (INa) play an important role in the pathogenesis of cardiac arrhythmias and 
may also contribute to the development of cardiomyopathies. We have recently demonstrated a critical 
role for the regulation of the voltage-gated sodium channel NaV1.5 in the heart by the serum and 
glucocorticoid regulated kinase-1 (SGK1). Activation of SGK1 in the heart causes a marked increase in 
both the peak and late sodium currents leading to prolongation of the action potential duration and 
an increased propensity to arrhythmia. Here we show that SGK1 directly regulates NaV1.5 channel 
function, and genetic inhibition of SGK1 in a zebrafish model of inherited long QT syndrome rescues 
the long QT phenotype. Using computer-aided drug discovery coupled with in vitro kinase assays, 
we identified a novel class of SGK1 inhibitors. Our lead SGK1 inhibitor (5377051) selectively inhibits 
SGK1 in cultured cardiomyocytes, and inhibits phosphorylation of an SGK1-specific target as well 
as proliferation in the prostate cancer cell line, LNCaP. Finally, 5377051 can reverse SGK1’s effects 
on NaV1.5 and shorten the action potential duration in induced pluripotent stem cell (iPSC)-derived 
cardiomyocytes from a patient with a gain-of-function mutation in Nav 1.5 (Long QT3 syndrome). 
Our data suggests that SGK1 inhibitors warrant further investigation in the treatment of cardiac 
arrhythmias.
Sudden cardiac death (SCD) is a leading contributor to mortality in the United States. With a current incidence 
of 180,000 to 450,000 per year1, the rate of SCD is likely to increase with the aging of the population. Disorders of 
sodium flux (INa) have recently been shown to play an important role in the pathogenesis of cardiac arrhythmias 
in both acquired and inherited arrhythmia syndromes2. Notably, mutations in the SCN5a gene that encodes the 
primary cardiac voltage-gated sodium channel, NaV1.5, cause multiple inherited arrhythmia syndromes, includ-
ing long QT syndrome 3 (LQT3), atrial fibrillation, and conduction disorders3. Interestingly, alterations in INa 
have also been observed in heart failure (HF), and may contribute to HF progression4, 5.
Medications that reverse abnormalities in INa may therefore have a role in the treatment of arrhythmias asso-
ciated with primary inherited channelopathies, as well as acquired heart diseases. Despite some success in using 
anti-arrhythmic drugs to modulate SCD risk in either animal or small human studies6, 7, attempts to target INa 
have not effectively been translated to the wider population, in part due to the pro-arrhythmic and negative ino-
tropic side effects of many anti-arrhythmic agents. Consequently, treatment of SCD in high risk patients relies on 
the implantation of internal cardiac defibrillators (ICDs), an invasive procedure associated with significant cost 
and potential morbidity8. Therefore, there is a clear unmet need for novel therapeutic approaches to the treatment 
of arrhythmias in these disease populations.
We have recently identified the serum and glucocorticoid-regulated kinase-1 (SGK1) as an important regula-
tor of INa in the heart4. Of the three known isoforms, SGK1 and SGK3 are predominately expressed in the heart9. 
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Unlike the related kinase Akt1, SGK1 is an important regulator of Na+ and K+ channels4, 10, 11. Prior studies have 
implicated SGK1 in the regulation of the epithelial Na+ channel, voltage-gated K+ and Na+ channels, and other 
ionic transporters mostly by regulating their trafficking to the cell membrane12–15. Notably, SGK1 appears to be 
activated predominantly in pathological conditions16, and inhibition of SGK1 either by germ-line ablation17 or by 
dominant-negative genetic inhibition does not cause a noticeable phenotype under basal conditions, but appears 
to be protective against pathological stress4. In contrast, chronic SGK1 activation in cardiomyocytes leads to a 
marked alteration in the sodium flux (but not of K+ or Ca2+ fluxes), prolongation of action potential duration 
(APD) in cardiomyocytes (CMs) and a markedly increased propensity for lethal ventricular arrhythmias4. These 
studies raise the possibility that small molecule inhibitors would be anti-arrhythmic in cardiac diseases through 
correction of abnormal INa while having little or no adverse consequences in normal hearts.
Over the past two decades, significant advances in targeted therapies have greatly changed the natural history 
of patient outcomes in many different cancers18. Because of increased survival there has been a growing recog-
nition that many traditional and advanced chemotherapeutics can adversely affect the cardiovascular system 
resulting in significant clinical complications19. More recently, the specific inhibition of key protein kinases has 
ushered in a new era of targeted therapy for oncology as dysregulation of protein signaling pathways are often 
associated with cancer progression. However, these therapies also have specific cardiac toxicities because many 
of signaling pathways targeted in cancer also are important in cardiac function and growth20. There now exists 
an enhanced awareness of the negative effects of chemotherapeutics on the heart, and the need for therapies that 
treat cancer while limiting cardiac side effects. Notably, SGK1 is in the rare category of kinases, whose inhibition 
may be of benefit both in heart disease and cancer.
Using computational design and in silico screening, we identified a novel class of inhibitors for SGK1 to use as 
pharmacological tools to test the hypothesis that SGK1 inhibition can decrease INa, shorten action potential dura-
tion and thereby rescue phenotypes associated with prolonged repolarization in CMs. Our results demonstrate 
proof of concept for SGK1 inhibition as a therapeutic target for cardiac arrhythmias and identify a small molecule 
lead, that with further medicinal chemistry can form the basis for novel and specific SGK1 inhibitors.
Results
CADD approach successfully identified a novel class of SGK1 inhibitory compounds. Based on 
previous data that SGK1 regulates INa4, we sought to identify small molecule SGK1 inhibitors for use as pharma-
cological probes to validate SGK1 as a therapeutic target in the treatment of cardiac arrhythmias. Using a combi-
nation of structure-based and ligand-based virtual screens (SBVS and LBVS) to query a reference library for small 
molecule inhibitors of SGK1, we clustered compounds based on previously validated metrics of activity (using a 
filtered library for Lipinski properties (rule-of-5)21). From a collection of ~500,000 small molecules meeting our 
initial activity requirements, we identified ~1000 compounds using requisite structure-function details extracted 
from other benchmarked kinase inhibitors.
In the absence of a high resolution structure of active SGK1 determined by X-ray crystallography or NMR 
spectroscopy at the time of the screening, we used comparative protein modeling to build a three-dimensional 
model for SGK1 based on known crystal structures of related proteins with acceptable sequence homology and 
protein folds. The model was later updated with the SGK-1 crystal structure (PDB code: 2R5T) and conforma-
tions of ‘activation loop’ sampled. This model (Fig. 1A) was used as the target for screening our initial 1st gen-
eration hits in silico. These small molecules were scored and ranked versus benchmarked kinase inhibitors that 
were doped into the library as reference compounds. These studies identified a final list of ~50 small molecules, 
representing 8 chemotypes that were then evaluated using an in vitro kinase assay to evaluate their ability to 
inhibit SGK1 kinase activity.
After validating the reproducibility and dynamic range of the in vitro kinase assay using recombinant 
GST-purified SGK1, we used this assay to evaluate the 1st generation small molecule inhibitors identified using 
our CADD platform. Compounds with demonstrable SGK1 inhibitory potential were re-screened using an 
8-point dosing curve to obtain IC50s. Several of the chemotypes had IC50s in the high nanomolar/low micro-
molar range, and one of these was chosen as a scaffold (R-substituted-methylene-2-thioxodihydropyrimidine-4,6 
(1H,5H)-dione) for the second generation screen.
The results from our initial studies were then used to refine the true-positive (active) and false-positive (less 
active, decoy) ligand-based pharmacophore models in an iterative discovery process. The chemotypes identi-
fied using the LVBS in our second-generation screen were filtered as detailed in the methods section to exclude 
chemicals that do not dock within the ATP-binding site of the SGK1 model. This 2nd generation screen yielded 
an additional 64 compounds that were again assessed using the in vitro kinase assay to exclude chemicals with 
poor SGK1 inhibitory activity. 9-point dose response curves on selected inhibitors that showed SGK1 inhibition 
at 20 μM dosage, identified several potential lead compounds (Fig. 1B). Based on a cell culture assay (see below), 
we focused on 5377051 and determined its IC50 (in cell culture) to be 2.1 μM (Fig. 1C).
SGK1 inhibitor 5377051 targets SGK1 activity in primary cultured CMs. As a first measure of the 
biological effectiveness of our putative SGK1 inhibitors in living cells, we examined the phosphorylation of an 
SGK1 target in cultured neonatal rat ventricular myocytes (NRVMs)22. Cells were infected with either an adeno-
virus expressing a constitutively active form of SGK1 (Ad.SGK1-CA) or a control adenovirus (Ad.GFP). At the 
time of infection, cells were also treated with various concentrations of SGK1 inhibitors 5377051 and 6410136, 
two of the molecules identified from the second-generation CADD-generated screen and validated as SGK1 
inhibitors in the in vitro kinase assay. Cell lysates were subjected to immunoblotting with an antibody against 
phospho (ser38)-glycogen synthase kinase beta (p-GSK3β), a well-established SGK1 substrate 48 hours after 
adenoviral infection. As expected, Ad.SGK1-CA caused an increase in p-GSK3β, which was inhibited by both 
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5377051 and 6410136 at sub-micromolar concentrations, suggesting inhibition of SGK1 activity in cardiomyo-
cytes (Fig. 2A,B, Supplementary Fig. 1).
Because SGK1 and Akt are structurally related but have different roles in the heart23, we next wanted to deter-
mine whether our putative SGK1 inhibitors would affect Akt signaling. NRVMs were infected with an adenovirus 
expressing constitutively active Akt124 (Ad.myr-Akt) or a control adenovirus, and treated with the inhibitors as 
above. We again assessed levels of p-GSK3β, which is a common substrate for Akt and SGK1. While infection 
of NRVMs with Ad.myr-Akt caused the expected increase in phosphorylated GSK3β, incubation with either 
5377051 or 6410136 failed to significantly inhibit Akt activity even at concentrations of 50 μM (Fig. 2C).
Finally, we directly compared the activity of our putative SGK1 inhibitors 5377051 and 6410136, to an SGK1 
inhibitor, EMD 638683, previously reported by Merck Serono25. In a similar experimental design, our lead com-
pounds showed equivalent SGK1 inhibition compared to the commercially available EMD 638683 (Fig. 2D).
SGK1 inhibitor 5377051 blocks the SGK1-mediated phosphorylation of NDRG1 and prolifera-
tion of a prostate cancer cell line. SGK1 is known to be up-regulated after androgen receptor activation 
in prostate cancer and plays an important role in androgen receptor dependent tumor proliferation and survival26. 
Accordingly, SGK1 inhibitors have been proposed as potential therapeutic approaches for prostate cancer27. We 
used the prostate cancer cell line, LNCaP, as a second independent assay for validation of the specificity and 
efficacy of our SGK1 inhibitors in a cell culture system, as has been previously reported by other investigators14. 
Cell lysates for LNCaP cells stimulated with the synthetic androgen R1881 with or without pre-incubation of 
compound 5377051, were assessed by immunoblotting for phosphorylation of the specific SGK1 target protein 
N-myc Downstream Regulated 1 (NDRG1), which is involved in stress responses and cell growth28. As expected, 
addition of R1881 led to a significant increase in phosphorylated NDRG1 (1.7 ± 0.2 fold p < 0.05). LNCaP cells 
transfected with SGK1-DN plasmid showed no increase in phosphorylation of NRDG1 after R1881, confirming 
that this effect is SGK1-dependent. The R1881-mediated increase in NRDG1 phosphorylation was also abrogated 
by treatment with 5377051 at concentrations as low as 500 nM (Fig. 3A,B).
We next assessed whether the SGK1 inhibitor would affect androgen-dependent cell proliferation in the 
LNCaP cell line. Addition of R1881 led to a significant increase in cell proliferation in LNCaP cells (1.5 ± 0.1 
fold, p < 0.05), which was inhibited with increasing concentrations of compound 5377051 (1.093 ± 0.08 p < 0.05, 
0.51 ± 0.18 p < 0.0001, 0.40 ± 0.1 p < 0.0001 fold respectively for the 500 nM, 5 μM and 50 μM doses compared 
with unstimulated cells, (Fig. 3C). Baseline cell proliferation was also inhibited at 50 μM and 100 μM although at 
these higher concentrations, we cannot exclude an effect of SGK1 inhibition on cell survival in addition to prolif-
eration. Thus the lead inhibitor identified blocks SGK1 activity in the LNCaP prostate cancer cell line in addition 
to primary CMs, thereby providing additional validity of SGK1 as a target of 5377051.
SGK1 activity regulates NaV1.5-mediated sodium flux. We had previously shown that transgenic 
mice with chronic activation of SGK1 in the heart had an increased propensity to ventricular arrhythmias, and 
Figure 1. Computer-Aided Drug Discovery for SGK1 inhibitors. (A) Virtual model for SGK1 used for CADD. 
(B) SGK inhibitors were R-substituted-methylene-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (left) 
derivatives with the two leading candidate structures shown (right). (C) Dose response curve for lead inhibitor 
5377051 (in presence of 1 ng of recombinant SGK1). Dilutions of the inhibitor were added to recombinant 
SGK1 and SGK1 activity was assayed using a fluorescence polarization assay in triplicates.
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that this was likely due to a marked alteration in INa4. As a prelude to determining the effectiveness of SGK1 
inhibition to treat ventricular arrhythmias, we first tested the hypothesis that SGK1 directly regulates the cardiac 
voltage-gated sodium channel (Nav 1.5) activity in a heterologous expression system.
HEK 293 cells stably expressing the SCN5a gene29, encoding NaV1.5, (referred to as HEK-NaV1.5) were tran-
siently transfected with a plasmid containing either a constitutively-active form of SGK1 (SGK1 S422D, referred 
to as SGK1-CA), a dominant negative form of SGK1 (SGK1 K127M, referred to as SGK1-DN) or a vector express-
ing GFP only. Cells were studied by whole-cell voltage clamp 24–48 hours after transfection.
Expression of SGK1-CA led to a significant increase in INa, while expression of SGK1-DN led to a decrease 
in sodium current density (Fig. 4A,C) compared to GFP controls. This was in agreement with our previous data, 
where constitutive activation of SGK1 in the heart led to an increase in INa in adult CMs isolated from the trans-
genic mice hearts4. In addition, HEK-NaV1.5 cells transfected with SGK1-CA had a leftward (hyperpolarizing) 
shift in steady state activation and inactivation (Fig. 4B), again recapitulating effects seen in CMs from SGK1-CA 
transgenic mice. This is also expected to increase the ‘window’ current, leading to an effective increase in INa. 
Conversely, the inhibition of SGK1 in cells transfected with SGK1-DN led to a decrease in INa current density 
suggesting substantial baseline SGK1 activity in the HEK cells (unlike in CMs) that drives sodium flux in these 
cells (Fig. 4C).
We had previously identified three candidate target sites for SGK1 phosphorylation on NaV1.5, including two 
sites in the linker between subdomains I and II, and one in the C-terminal domain4. The first two sites had previ-
ously been shown by others to influence channel biophysical properties in oocyte expression experiments30, while 
the third site had not previously been identified. Mutation of these serines to alanines (to abolish SGK1 phos-
phorylation) also abolished the hyperpolarization shifts in the activation and inactivation curves described above 
(data not shown). Interestingly, mutation of the C-terminal residue threonine to alanine (T1590A), effectively 
preventing the phosphorylation by SGK1 at that site, dramatically reduced the SGK1-induced increase in sodium 
flux (Fig. 4D,E). Taken together, our data suggest that SGK1 regulates INa through multiple phosphorylation sites, 
and inhibition of SGK1 would be expected to reduce INa in pathological conditions.
Figure 2. Inhibition of SGK1 in cultured cardiomyocytes by lead compounds. (A) Inhibition of SGK1 activity 
assessed by GSK3β phosphorylation in CMs infected by Ad.SGK1-CA. (B) Different concentrations of 5377051 
were assessed at 48 hours after treatment with immunoblotting (left) and quantitated (right). (C). Effect of 
SGK1 inhibitors on Akt-induced phosphorylation of GSK3-beta in CMs infected by Ad.-myr-Akt was assessed 
by immunoblotting. (D) Comparison of potency of 10 micromolar compounds 5377051, 6410136 with the 
published inhibitor EMD63863. Immunoblots were cut to facilitate the incubation the same samples with 
multiple antibodies and cropped for clarity. All samples were loaded contiguously as shown. Quantified data are 
the composite of three independent experiments, each with three technical replicates. Each experimental set 
was conducted with the same batch of adenovirus.
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SGK1 inhibitor 5377051 reverses the SGK1-induced changes in INa. Because we had previously 
found that SGK1 regulates INa, we sought to determine if pharmacological SGK1 inhibition could modulate INa in 
the HEK-NaV1.5 cells. Bath application of compound 5377051 at 10 μM resulted in a significant reduction in INa 
(Fig. 5A,B). Quantification of peak INa with and without co-expression of SGK1-CA in the presence of the inhibi-
tor demonstrated an 80–90% reduction in sodium current, SGK1-CA (Baseline: 251.6 ± 62.2 pA/pF, +Inhibitor: 
23 ± 9.8 pA/pF, n = 4, p < 0.05, Fig. 4B), RFP only (Baseline: 161.5 ± 32.0 pA/pF, +Inhibitor: 36.2 ± 17.4 pA/pF, 
n = 5, p < 0.005, Fig. 5B). The level of reduction of INa was similar to what was noted with genetic SGK1 inhibi-
tion by SGK1-DN expression. The inhibition by compound 5377051 occurs over approximately 6 minutes with a 
half-time of 158 ± 31.2 s (n = 6) (Fig. 5C).
To confirm that compound 5377051 was not a direct channel blocker we expressed the phosphorylation 
mutant T1590A in HEK cells and measured the peak INa. There was no significant reduction in peak current of 
cells expressing the T1590A mutant channels when measured at a time point where there was more than 70% 
inhibition of wild-type NaV1.5 (Fig. 5D). While there was a reduction of INa in some cells expressing the T1590A 
mutation, the latency of inhibition was significantly prolonged (Fig. 5E). Together these data suggest that the 
effect of the SGK1 inhibitor on INa was critically dependent on SGK1 phosphorylation of Nav1.5, and that aboli-
tion of the phosphorylation sites on Nav1.5 also abolished the effect of 5377051. Hence our results supported our 
hypothesis that the action of compound 5377051 on INa current density was mediated by SGK1 inhibition and not 
an ‘off-target’ effect as a direct channel blocker.
SGK1 inhibition in mammalian cardiomyocytes selectively reduces the late sodium current 
INaL. Multiple lines of evidence have demonstrated that the late sodium current INaL is unregulated in patholog-
ical settings31. Mutations that lead to congenital long QT syndrome type 3 often increase the persistent sodium 
current and predispose cells to early after depolarizations (EADs) and ventricular arrhythmias32. Importantly, the 
increased arrhythmogenesis in the transgenic mice with SGK1 activation in the heart, could be attributed to an 
increase in INaL4. However, the HEK-NaV1.5 cells do not demonstrate appreciable INaL, likely due to the fact that 
the full voltage-gated sodium channel macro-molecular complex is not effectively reconstituted in this heterolo-
gous expression system. We therefore assessed the effect of pharmacological inhibition of SGK1 on native INaL in 
cultured primary cardiomyocytes (NRVMs).
Whole-cell recordings demonstrated a characteristic rapidly activating and inactivating inward sodium cur-
rent to a single depolarizing pulse (Fig. 6A). Incubation with our lead compound for at least 5 minutes, did not 
result in a significant decrease in peak INa (Fig. 6B). While expectedly, the baseline INaL was small in native car-
diomyocytes, there was a notable reduction in the measured late current after incubation with the compound 
(Fig. 6C), which appeared selective over the peak current (Fig. 6D). These data suggest that inhibition of SGK1 in 
native cardiomyocytes preferentially inhibits the late sodium current and may be a potential therapeutic target for 
forms of inherited heart disease such as long QT syndrome.
Inhibition of SGK1 rescues 2:1 AV block due to prolonged QT in the breakdance zebrafish 
mutants. The zebrafish breakdance mutant (bkd−/−) fish is a unique model of action potential prolongation 
Figure 3. Validation of lead SGK1 inhibitor compound in a prostate cancer cell line. (A) Western blot 
demonstrating inhibition of SGK1 by compound 5377051 blocked the phosphorylation of SGK1 target 
NDRG-1 in response to the androgen analog R1881. (B) Quantification of NDRG-1 phorsphorylation. (C) 
5377051 inhibited the proliferation of LNCaP prostate cancer cell line induced by the androgen analog R1881 
as assayed by Cy-quant assay. Immunoblots were cut to facilitate the incubation the same samples with multiple 
antibodies and cropped for clarity. All samples were loaded contiguously as shown.
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due to a mutation in the zebrafish homologue of the KCNH2 channel recapitulating human LQT2 syndrome33. 
The phenotypic manifestation of the prolonged QT interval in the bkd−/− fish is the presence of functional 2:1 
atrioventricular (AV) block (as is sometimes seen at in human neonates with LQTS as a consequence of prolonged 
repolarization and effective refractory period34), and previous high throughput experiments have taken advan-
tage of this easily quantifiable phenotype to screen for compounds that shorten the action potential duration 
(APD) and ‘rescue’ the 2:1 AV block (Fig. 7A)35. This type of compensatory QT shortening has recently been 
demonstrated as a potential therapy in congenital long QT syndrome by inhibiting INa in a patient with Timothy 
syndrome36. Bkd−/− fish represent an animal model of long QT syndrome that provides a unique system to rapidly 
test the efficacy and potential toxicity of bio-active compounds in an animal model37.
To determine if SGK1 inhibition would also shorten the APD in the bkd−/− mutants, fish were injected with 
500 μM of SGK1 morpholino or SGK1-DN mRNA (that inhibits SGK1 activity in a dominant negative fashion) 
at the 1–2 cell stage and scored for the presence or absence of 2:1 block at 99 hours post fertilization. The SGK-1 
morpholino rescued 58% of mutants, compared with 5% spontaneous reversion in control-scrambled mor-
pholino injections (Fig. 7B). Expression of SGK1-DN was even more potent, resulting in rescuing 90% of mutant 
fish (Fig. 7B). Thus two independent genetic approaches to SGK1 inhibition rescue the 2:1 AV block phenotype in 
this zebrafish model of LQTS. While the mechanism of QT shortening and rescue in this model by genetic SGK1 
inhibition was not clearly evident, we exploited this finding to test the efficacy of our SGK1 inhibitors.
Pre-incubation of zebrafish homozygous for the breakdance mutation (Bkd−/−) for 24 hours with compound 
5377051 resulted in effective rescue of 2:1 AV block in a dose-dependent fashion (Fig. 7C,D). The percent res-
cue with 45 μM of the inhibitor was similar to that seen with administration of a morpholino against SGK1. 
Minimal toxicity was seen at even higher concentrations of the inhibitor and did not appear to be dose-dependent 
(Fig. 7C). These data suggested that SGK1 inhibition by 5377051 may be potentially therapeutic for arrhythmic 
conditions associated with a prolonged QT interval.
SGK1 inhibitor 5377051 shortens APD in human induced pluripotent stem cell (iPSC)-derived 
cardiomyocytes from a patient with LQT3. To examine the therapeutic effects of SGK1 inhibition in 
a relevant disease model, we tested our lead compound in cardiomyocytes differentiated from human induced 
pluripotent stem cells (hiPSCs) that offer a unique model to study inherited arrhythmia disorders38. Application 
of the SGK1 inhibitor did not significant prolong the action potential duration (APD) of hiPSC-derived 
Figure 4. SGK1 regulates NaV1.5 channel function. (A) Expression of SGK1-CA in HEK-NaV1.5 cells leads 
to increase in INa density. Inset scale = vertical: 50 pA/pF, horizontal: 2 ms. (B) SGK1 activation leads to a 
hyperpolarizing shift of steady state activation and inactivation curves for INa. (C) Peak sodium currents 
are increased with expression of SGK1-CA while inhibition of SGK1 by the dominant negative kinase dead 
SGK-1 (SGK1-DN) leads to decrease in INa density (*p-value < 0.005 by one way ANOVA, n = 5–11 for each 
condition). (D) Mutation of a novel SGK1 putative site T1590A leads to abrogation of the increase in INa with 
SGK1 activation. (E) Quantification of peak sodium currents (NS = non-significant change, n = 3–5 for each 
condition).
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cardiomyocytes (hiPSC-CMs) from a normal patient as measured by the fluorescent voltage sensor Arclight39 
(Fig. 8A). In contrast incubation of our lead compound with hiPSC-CMs derived from a patient with a sodium 
channel defect causing LQT3 (Nav1.5-N406K)40, results in significant shortening of the APD and correction of 
the abnormal phenotype (Fig. 8B,C). These data suggest that SGK1 inhibition with our lead compound 5377051 
can reverse the defect seen in LQT3 at a cellular level in a model relevant to human disease.
Discussion
Alteration of INa has been implicated in both inherited and acquired arrhythmia syndromes, and plays a causative 
role in the etiology of some ventricular arrhythmias. Here we show that SGK1 is an important regulator of INa, and 
that SGK1 inhibition represents a therapeutic strategy for the treatment of certain cardiac arrhythmias.
SGK1 inhibitors have previously been developed in the context of treatment for prostate cancer and one of 
these inhibitors has also been tested in vivo as an anti-hypertensive25. However, SGK1 inhibition as a novel thera-
peutic approach to modulating INa has not been previously explored to our knowledge. Using rational drug design 
along with directed screening, we have identified a novel scaffold for SGK1 inhibition that retains specificity for 
SGK1 over the closely related kinase Akt1. The compound 5377051 appears to inhibit SGK1 effectively and spe-
cifically in two different cell types, making it unlikely that our results are due to off-target effects. We anticipate 
that derivatives of this compound or other SGK1 small molecule inhibitors may have potential not only as a 
treatment for arrhythmias in inherited and acquired cardiac disease with abnormalities in INa flux, but may also 
protect against adverse cardiac remodeling as has been seen with genetic SGK1 inhibition in the heart4. Finally, as 
most kinase inhibitors used in oncological diseases have adverse cardiovascular effects, SGK1 inhibitors have the 
unique property of being potentially beneficial in both classes of disease.
While the potency of 5377051 in vitro was less than the potency of other kinase inhibitors, the IC50 in 
cell-based assays was as little as 1–5 μM with a minimal effect on the related kinase Akt at the same concentra-
tions. While additional refinement through medicinal chemistry will undoubtedly be necessary (in addition to 
testing against other kinases to gauge off-target kinase inhibition), our lead compound represents a useful tool to 
validate SGK1 as a relevant target for sodium channel modulation.
In this study, our single cell electrophysiology experiments demonstrated the potency, biophysical effects and 
kinetics of the SGK1 inhibition on NaV1.5 channel activity, recapitulating many of the effects of persistently active 
Figure 5. Inhibition with lead compound 5377051 modulates INa by inhibiting SGK1. (A) Addition of 5377051 
at 10 uM significantly decreases INa even with co-expression of SGK1-CA. (B) Quantification of changes in 
peak sodium current with addition of inhibitor 2 (5377051) with and without co-expression of SGK1-CA 
(n = 4–6 per condition, *p-value < 0.05). (C) Representative time course of inhibition by compound 5377051 as 
compared to addition of DMSO. (D) Average time for inhibition demonstrating a half-time of 200 s (n = 4).
www.nature.com/scientificreports/
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SGK1 on NaV1.5 we had previously reported. These effects were further replicated by acute application of the lead 
compound 5377051 during whole cell patch-clamp recordings. The time course of inhibition was on the order 
of several minutes, which would be slow for channel inhibition by a typical pore blocker, but consistent with a 
post-translational mechanism. In addition, mutation of the putative SGK1 phosphorylation T1590 to alanine 
significantly altered the sensitivity of the channel to SGK1 inhibition by 5377051, further demonstrating that the 
effect is not due to direct channel blockade. In contrast to CMs, the dramatic degree of inhibition of INa in HEK 
cells by either genetic or pharmacological inhibition of SGK1 is likely secondary to a high level of activity of SGK1 
in HEK cells because of their epithelial lineage.
Unlike our prior studies4, we did not observe the increase in late sodium current in our heterologous expres-
sion system in comparison to isolated cardiomyocytes from transgenic mice expressing constitutively active 
SGK1, likely due to the absence of the associated subunits such as the beta-subunits which can significantly 
modulate late current levels in HEK cells41 or related to reductions in external sodium necessary to fully clamp 
the peak current. However, in primary cardiomyocytes, our lead compound selectively inhibited the late sodium 
current over the peak current. Taken together our data strongly suggest that SGK1 is a potent modulator of the 
sodium channel and pharmacologic inhibition of SGK1 activity inhibits the late sodium current that is often asso-
ciated with pathologic conditions4. Our studies provide ‘proof-of-concept’ of SGK1 inhibition as a therapeutic 
target for treating cardiac arrhythmias.
Extensive research over the last two decades has demonstrated that ion channels are complex macromolecular 
machines and parts of signaling networks with a diverse array of associated proteins. The cardiac sodium channel 
NaV1.5 is modulated by multiple post-translational modifications including phosphorylation42 and acetylation43. 
These modifications can directly affect the biophysical properties of the channel, change the number of available 
protein complexes at the plasma membrane or modulate associated proteins that can further affect channel func-
tion. While traditional ion channel blockers have efficacy in treating certain types of arrhythmias, modulation of 
ion channel post-translational modification may provide more fine-tuned therapy without the pro-arrhythmic 
side effects commonly seen in typical ion channel blockers. In support of this, there appears to be a ‘plateau’ 
effect for SGK1 inhibition in vivo, both in mice with chronic SGK1 inhibition in cardiomyocytes (which do 
not have shorter repolarization4), and in human iPSC-derived cardiomyocytes from normal patients (Fig. 7A). 
Furthermore, inhibition of hERG, a major concern for anti-arrhythmic therapies is not seen with the SGK1 inhib-
itor 5377051. Assessment of effect of 5377051 in HEK cells transfected with hERG, demonstrated an increase in 
Figure 6. Inhibition of SGK1 in cardiomyocytes selectively reduces the late sodium current INaL. (A) 
Representative INa from NRVMs at baseline and after acute treatment with compound 5377051 demonstrates 
preferential reduction of late current. (B) Quantification of the peak current does not demonstrate a significant 
reduction with administration of the inhibitor (Peak current density: Pre = −560.1 ± 180 pA/pF versus 
Post = −396.1 ± 230.4 pA/pF). (C) Selective inhibition of native late sodium current with incubation of the lead 
compound (Late current density: Pre = 5.12 ± 2.4 pA/pF versus Post = −2.3 ± 1.5 pA/pF). (D) Relative decrease 
in peak to late current ratio. (*p-value < 0.05, †p-value = non-significant, n = 6 for all experiments).
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tail currents of hERG in HEK cells treated with our lead compound compared to control (Supplemental Fig. 2), 
although this enhancement of hERG tail currents in HEK cells do not appear to cause any meaningful shortening 
of the action potential in iPSC-cardiomyocytes from a normal patient.as shown in Fig. 8A. While future deriva-
tive compounds will have to be thoroughly tested for off-target activity against other ion channels our preliminary 
results clearly rule out inhibition of the hERG channel by this class of compound while demonstrating a possible 
positive effect on hERG tail currents.
Finally, to test the feasibility of the compound as a functional cardiovascular drug, we demonstrated effective 
treatment of the zebrafish breakdance model of Long QT syndrome with minimal toxicity. The mechanism of 
rescue is likely secondary to an inhibition of inward sodium current that compensates for the impaired repolar-
ization from reduced potassium flux, although this hypothesis was not verified. Alternatively, the rescue may be 
in part due to direct enhancement of hERG channel activity (Supplemental Fig. 2). While the exact mechanism 
for rescue of the breakdance phenotype was not elucidated, these data demonstrate the efficacy and low toxicity 
of the inhibitor in a more complex biologic system and suggest that SGK1 inhibitors could be used effectively in 
Long QT syndrome caused by a range of ion channel mutations.
Finally, to prove the validity of SGK1 inhibition in treating human arrhythmia disorders, we demonstrated the 
efficacy of SGK1 inhibitor in shortening the action potential duration in human iPSC-derived cardiomyocytes 
from a patient with known LQT3 due to a gain-of-function mutation in NaV1.5. These experiments provide clin-
ical relevance of SGK1 as a target for treatment of ventricular arrhythmias in conditions with abnormal increases 
in sodium flux.
In conclusion, in this study, using CADD-based small molecule inhibitors of SGK1 as pharmacological probes 
to complement genetic inhibition of SGK1, we have demonstrated ‘proof-of-concept’ SGK1 inhibition as a thera-
peutic target for ventricular arrhythmias. While our lead compound represents a useful pre-clinical tool for target 
validation, future efforts at improving the potency and specificity of SGK1 inhibitors using medicinal chemistry 
will be needed prior to further testing in relevant pre-clinical models such as disease-specific iPSC-derived cardi-
omyocytes and animal models of long QT syndrome.
Methods
Computer Aided Drug Discovery (CADD) of SGK1 inhibitor chemotypes. All molecular modeling 
operations were performed in the SYBYL-X (Certara/Tripos) and/or BIOSOLVEIT (BioSolveIT, GmBH) molec-
ular modeling packages, running on Dell Precision 690 workstations with 8 CPUs, 10 GB memory and RHE 
Figure 7. Treatment with SGK1 inhibitor 5377051 restores prolonged APD in a cellular model of LQT3. (A) 
Representative fluorescent tracings of spontaneous action-potentials from wild-type hiPSC-CMs expressing 
ArcLight with or without the SGK1 inhibitor 5377051 quantified by measuring the action potential duration 
at 80% repolarization (APD80) (WT + DMSO, 244 ± 9 ms, n = 15 versus WT + 5377051, 235 ± 8 ms, n = 11) 
(B) Fluorescent action potential recordings from LQT3 hiPSC-CMs with 5377051 demonstrate significant 
shorting of the APD80 (LQT3 + DMSO, 278 ± 7 ms, n = 22 versus LQT3 + 5377051, 218 ± 10 ms, n = 16). 
(C) Cumulative APD data from WT and LQT3 hiPSC-CMs with and without SGK1 inhibitor. Statistics was 
performed by applying a one-way ANOVA with Bonferroni’s post hoc correction: *P < 0.05, **p < 0.01 and 
***P < 0.001, versus LQT3 + DMSO.
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Linux 5 OS. The chemical libraries employed in the virtual screening primarily included Chembridge (www.
Hit2Lead.com, San Diego, CA), pre-filtered for the Lipinski rule-of-five for drug-like properties. Ligand based 
virtual screen (LBVS) was performed using Sybyl, in which we used 2D and/or 3D conformations of known “lig-
ands” including many of the identified kinase inhibitors (independent of target) on the basis of kinase inhibitory 
properties to construct multiple 3D pharmacophoric fingerprints to rapidly screen small molecule libraries in 
silico. The 3D-pharmacophore fingerprint/key we used is an extension of the 2D-pharmacophore models that 
are commonly used by others44. Briefly, these keys are comprised of functional groups responsible for mediating 
critical ligand receptor interactions and are represented as potential pharmacophore points (PPPs) in three-di-
mensional space. These PPPs are comprised of triplets or quartets with a triplet PPP using three pharmacophore 
points that include requisite distance data and/or quartets that are comprised of four pharmacophore points 
along with six distance and/or chirality constraints45. High-throughput docking (HTD)-based virtual screening 
was performed using FlexX and FlexX-ensemble, which consider the conformational flexibility within the target 
interface, in combination with a powerful incremental construction algorithm that allows the complexity and 
size of the ligand to be iteratively constructed from a predefined base fragment46. The algorithm used by FlexX is 
based on the model of molecular interactions defined by Bohm47 and Klebe and is divided into three segments: 
core or base selection, core placement, and incremental complex construction48. After docking, a variety of scor-
ing functions are used to energetically assess each calculated pose, which take into account forces involved in this 
interaction as well as the affinity between the interacting atoms. Importantly, we performed cross docking; pose 
generation validation studies using additional HTD algorithms including: Surflex-Dock (TRIPOS) and/or Glide 
(Schrödinger) to ensure our hit list was not biased towards a single HTD algorithm/approach.
SGK1 kinase assay. To screen CADD-generated SGK1 inhibitor candidates, we used a fluorescence 
polarization-based in vitro kinase assay (Upstate). Briefly, this assay utilizes a phosphorylated peptide that 
is labeled with a green fluorescent dye and increases its fluorescence polarization value upon binding with a 
phospho-specific antibody. We first validated the reproducibility and dynamic range of the assay using different 
concentrations of a recombinant GST-purified SGK1 and determined the EC50 of the recombinant kinase to be 1 
ng. This assay was then used to evaluate the 1st and 2nd generation small molecule inhibitors identified using our 
CADD platform. Initial activity screening was done at a concentration of 50 μM to ensure we did not miss com-
pounds with activity and several compounds had demonstrable SGK1 inhibitory potential. These inhibitors were 
re-screened using an 8 point dosing curve to obtain IC50s for several of the inhibitors, and used for the second 
round of CADD to generate an additional 64 compounds for further testing in this kinase assay.
Figure 8. SGK1 inhibition rescues a zebrafish model of long QT. (A) Still frame image of zebrafish heart with 
chamber labels (A = atrium) (V = ventricle). Representative tracings of chamber wall position demonstrating 
2:1 AV block in mutant bkd−/− zebrafish (upper panel) and with rescue of the phenotype (lower panel). (B) 
Knock-down with SGK1 morpholino or inhibition of SGK1 (500 μM SGK1-DN mRNA) in the breakdance 
zebrafish mutants with long QT at 1–2 cell stage leads to significant rescue of 2:1 AV block at 99 hpf stage (5% 
spontaneous reversion at this stage); *p-value < 0.05 by Z-test. (C) Compound 5377051 added at 48 hours post 
fertilization (hpf) and assessed at 72 hpf for rescue of phenotype 2 with superimposed rescue (solid line) and 
toxicity (dashed lines) curves shown on left (C) and representative bar graph on right (D). *p < 0.05 by Z-test.
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SGK1 inhibition in cardiomyocytes. All experiments and protocols including animal procedures for 
isolation of cardiomyocytes, were approved by the Institutional Biosafety Committees (IBCs) and institutional 
IACUCs at both Beth Israel Deaconess Medical Center and Massachusetts General Hospital in accordance with 
institutional and national guidelines. To investigate the activity of SGK1 in cardiomyocytes, 2 × 106 neonatal rat 
ventricular myocytes (NRVMs) were plated on 60 mm plates. 24 h after plating, serum was removed and infected 
with SGK1-CA virus and treated with SGK1 inhibitors. Twelve hours after infection and treatment, the media 
was changed and cells were treated again. Twelve hours following the second treatment NRVMs were harvested 
and separated by gel electrophoresis.
SGK1 inhibition in prostate cancer cell line LNCaP. For Western Blotting, 2 million LNCaP (ATTC) 
cells were plated on 60 mm dishes in RPMI-1640 containing 10% FBS and 1% pen-strep antibiotic. After 24 h 
plating cell media was replaced with RPMI-1640 containing 10% charcoal stripped fetal bovine serum to 
decrease androgen interference from the media. Cells were either transfected with SGK-DN or treated with drug 
(500 nM–100 μM and treated with the synthetic androgen analog R1881 (1 nM). Cells were treated at 0, 12 and 
24 h and harvested 32 h after first treatment. Proteins were separated by gel electrophoresis using 50 μg of protein 
per well. P-NDRG1 (Cell Signaling) was normalized to GAPDH and data presented as fold change from control. 
For CyQUANT cell proliferation assay (Life Technologies), LNCaP cells were plated at 25,000 cells/well in a 96 
well plate in plating media. 24 h after plating, media was changed to RPMI-1640 containing 10% charcoal stripped 
fetal bovine serum. Cells were treated with either 5377051, R1881 (1 nM) or both every 24 h for 72 h. Cell prolif-
eration was measured using the manufacturer’s protocol.
Cellular Electrophysiology. HEK-293 cells with stably-transfected SCN5a were voltage clamped using the 
whole-cell patch-clamp configuration as previously described29. To determine the effects of either constitutively 
(SGK1-CA) active or dominant negative (SGK1-DN) SGK1, respective plasmids were transfected for 4–6 hours 
with Lipofectamine 3000 (Life Technologies) and recordings were performed the following day. To improve 
the selection of transfected cells SGK1-CA was fused to mCherry by standard molecular biology techniques. 
All control cells were transfected with constructs expressing GFP or mCherry alone. All INa recordings (Axon 
Instruments) were performed at room temperature with patch pipettes of 1.5–2.5 MΩ tip resistance when filled 
with pipette solution containing (in mM): NaCl 5, CsCl 40, glutamate 80, CsOH 80, Mg-ATP 5, EGTA 5, HEPES 
10, CaCl2 1.5 (free [Ca2+] = 100 nM, pH 7.2 with CsOH, LJP = +5 mV). The bath solution contained (in mM) 
NaCl 50, MgCl2 2, CaCl2 1.2, NMDG 80, HEPES 10, Glucose 10 (pH 7.4). In all experiments, recordings started 
5 min after establishment of the whole-cell mode to permit stabilization of current amplitude, voltage dependence 
and kinetics of gating. Standard voltage protocols were used for assessment of the voltage-dependence of activa-
tion/inactivation, recovery from inactivation. To determine the membrane potential for V1/2 and the slope factor 
k, steady state inactivation data were fit with a Boltzmann function of the form: I/Imax = {1 + exp[(V − V1/2)/k]
} − 1. For late sodium channel recordings, NRVMs were isolated and cultured on laminin-coated glass coverslips. 
Whole-cell recordings were performed 5 minutes after break-in and the external solution was similar to those 
used in the recordings of HEK293 cells, 50 mmol NaCl but without NMDG. We performed at least five current 
recordings per cell with an interval of 30 seconds between recordings, without drug and after bath exchange with 
the inhibitor (50 μmol/L). Currents before and after drug administration were averaged (n = 7 cells).
Maintenance and differentiation of iPSCs into Cardiomyocytes. Skin fibroblasts were obtained 
from a healthy volunteer and reprogrammed into pluripotent stem cells by standard methods. HiPSCs from a 
patient with LQT3 were previously described40. Human iPSCs were maintained in Essential 8 media and passaged 
every 3–5 days as single cells on Geltrex-coated plastic dishes (Invitrogen). Differentiation was performed as 
described elsewhere by sequential inhibition of GSK3 and the Wnt signaling pathways49, 50. Spontaneously beating 
CMs between days 20 and 30 were dissociated with 0.25% Trypsin-EDTA (GIBCO), re-plated on Geltrex-coated 
96-well plates and maintained in RPMI 1640 medium with B27 complete supplement (Invitrogen) as described 
previously50.
Optical Imaging of ArcLight Fluorescence in hiPSC-CMs. Dissociated hiPSC-CMs were transduced 
with lentivirus carrying pLenti-CMV-ArcLight for 72 hr50. 5 days after the onset of transduction, CMs were 
incubated with DMSO or 5377051 (10 μmol/L) for 24 hrs. Cells were then imaged with a Nikon Eclipse Ti-U 
inverted microscope, a Nikon CFI S Fluor 20X objective, an ORCA-Flash2.8 C11440-10C digital CMOS camera 
(Hamamatsu) and the MetaMorph Microscopy Automation and Image Analysis Software at 37 °C. ArcLight flu-
orescence was obtained with a FITC filter set and a SOLA SE light engine for illumination (Lumencor). Images 
were recorded at 1000 frames per second. ArcLight recordings were analyzed using a custom-written Matlab 
program. Action potential duration at 80% repolarization (APD80) was calculated to be the time interval between 
when signals reached 50% of the difference in fluorescence between the initiation and maximal height of an 
upstroke, and 80% of the return to diastolic baseline. The peak-to-peak interval was used to determine beating 
rate and all APD80 analyzed was corrected to reflect ADP80 at 1 Hz. Optical AP tracings are presented as −ΔF/
F0, where F0 is the resting diastolic fluorescence.
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